The Evolution of Amyloid Antibodies

There have been a lot of different antibodies that have targeted amyloid throughout the years, and I think we've seen a lot of trials that have been unsuccessful. One of the major things that facilitated more success in the past few years is the development of biomarkers that can actually directly measure plaques and tangles in the living brain. The first drug that made it to the clinic was a monoclonal antibody called Adjurcanumab. And so prior to a drug that we will talk about today, there are two antibodies that are approved for clinical use.